Abstract
The success rate of novel medical entities that are submitted for registration by the regulatory agencies and followed successful marketing has been stagnating for the past decade. Failure in efficacy and safety continue to be the prime hurdles and causes of failure. Translational medicine is a new function within the pharmaceutical industry R&D organization aimed to improve the predictability and success of drug discovery and development. Biomarkers are the essence of the translational medicine strategy focus on disease biomarker, patient selection, pharmacodynamic responses (efficacy and safety) target validation, compound-target interaction). Successful deployment of biomarkers research, validation and implementation is adopted and embraced as key strategy to improved the drug discovery and development towards new medical entities.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Biomarker Definition Working Group. Biomarkers and surrogate biomarkers endpoints: preferred definitions and conceptual framework. Clin Pharmacol Theraputics 2001; 69:89–95.
Trusheim R, Ernst R, Berndt ER et al. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery 2007; 6:287–293.
Feuerstein GZ, Rutkowski JL, Walsh FS et al. The role of translational medicine and biomarkers research in drug discovery and development. American Drug Discovery 2007; 2:23–28.
US Food and Drug Administration (FDA) report. Challenge and opportunity on the critical path to new medical products. http:www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf (2004).
Zammit S, Allebeck P, David AS. A longitudinal study of premorbid IQ Score and risk of developing schizophrenia, bipolar disorder, severe depression and other nonaffective psychoses. Arch Gen Psychiatry 2004; 61(4):354–60.
Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67(10):e12.
Wynn JK, Green MF, Sprock J et al. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res 2007; 95(1–3):134–42.
Iritani S. Neuropathology of schizophrenia: A mini review. Neuropathology 2007; 27(6):604–8.
Dorph-Petersen KA, Pierri JN, Perel JM et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005; 30(9):1649–61.
Berry DA. Bayesian Clinical Trials. Nature Drug Discovery Reviews 2006; 5:27–36.
Gallo P, Chuang-Stein C, Dragalin V et al. Adaptive design in Clinical Drug Development-an executive summary of the PhRMA working group. Journal of Biopharmaceutical Statistics 2006; 16:275–283.
Krams M, Lees KR, Hacke W et al. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN). Stroke 2003; 34:2543–2548.
Kurzrock R. Studies in target-based treatment. Molecular Cancer Theraputics 2007; 6:1477.
Hampton T. Trials assess Myasthenia Gravis therapies. JAMA 2007; 298–1:29–30.
Chien KR. Herceptin and the heart—a molecular modifier of cardiac failure. N Engl J Med 2006; 354:789–790.
Hershey J, Steiner B, Fischli W et al. Renin Inhibitors: An antihypertensive strategy on the verge of reality. Drug Development Today 2005; 2:181–185.
Simmons D. What makes a good anti-inflammatory drug target? Drug Discovery and Development 2006; 5/6:210–219.
Gombar C, Loh, E. Learn and Confirm. Drug Discovery and Development 2007; 10, 22–27.
Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharm Ther 2007; 61: 275–291.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Day, M., Rutkowski, J.L., Feuerstein, G.Z. (2009). Translational Medicine—A Paradigm Shift in Modern Drug Discovery and Development: The Role of Biomarkers. In: Guzmán, C.A., Feuerstein, G.Z. (eds) Pharmaceutical Biotechnology. Advances in Experimental Medicine and Biology, vol 655. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1132-2_1
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1132-2_1
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1131-5
Online ISBN: 978-1-4419-1132-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)